• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

认知衰退人群的个性化生活方式干预中的认知改善观察。

Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.

机构信息

Solcere, Encinitas, CA, USA.

Helfgott Research Institute, National University of Natural Medicine, Portland, OR, USA.

出版信息

J Alzheimers Dis. 2023;94(3):993-1004. doi: 10.3233/JAD-230004.

DOI:10.3233/JAD-230004
PMID:37355891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10473097/
Abstract

BACKGROUND

Alzheimer's disease (AD) is a chronic condition marked by progressive objective cognitive impairment (OCI). No monotherapy has substantially altered disease progression, suggesting the disease is multifactorial and may require a multimodal therapeutic approach.

OBJECTIVE

We sought to determine if cognitive function in a sample with OCI would change in response to a multimodal, individualized care plan based on potential contributors to cognitive decline (e.g., nutritional status, infection, etc.).

METHODS

Participants (n = 34) were recruited from the San Diego, CA area. The multimodal intervention included lifestyle changes (i.e., movement, diet, and stress management), nutraceutical support, and medications. It was delivered pragmatically over four clinical visits, and outcome measures were gathered at four study visits, occurring at baseline, one, three, and six months (primary endpoint). Study participants received weekly phone calls for nutrition support throughout study participation. Outcome measures included the Cambridge Brain Sciences (CBS) battery, and the Montreal Cognitive Assessment (MoCA).

RESULTS

At 6 months, mean MoCA scores improved from 19.6±3.1 to 21.7±6.2 (p = 0.013). Significant improvement was observed in mean scores of the CBS memory domain [25.2 (SD 23.3) to 35.8 (SD 26.9); p < 0.01] and CBS overall composite cognition score [24.5 (SD 16.1) to 29.7 (SD 20.5); p = 0.02]. All CBS domains improved.

CONCLUSION

Multiple measures of cognitive function improved after six months of intervention. Our results support the feasibility and impact of a multimodal, individualized treatment approach to OCI, warranting further research.

摘要

背景

阿尔茨海默病(AD)是一种以进行性客观认知障碍(OCI)为特征的慢性疾病。没有单一疗法能显著改变疾病进展,这表明该疾病是多因素的,可能需要采用多模式治疗方法。

目的

我们旨在确定在基于认知能力下降的潜在因素(如营养状况、感染等)制定的多模式个体化护理计划的作用下,OCI 患者的认知功能是否会发生变化。

方法

参与者(n=34)从加利福尼亚州圣地亚哥地区招募。多模式干预包括生活方式改变(即运动、饮食和压力管理)、营养支持和药物治疗。该干预措施在四次临床访视中以实用的方式进行,在四个研究访视中(基线、1 个月、3 个月和 6 个月时为主要终点)收集结果。研究参与者在整个研究期间每周都会通过电话获得营养支持。结果评估指标包括剑桥大脑科学(CBS)测试和蒙特利尔认知评估(MoCA)。

结果

6 个月时,MoCA 评分从 19.6±3.1 提高到 21.7±6.2(p=0.013)。CBS 记忆域的平均得分显著提高[25.2(23.3)到 35.8(26.9);p<0.01]和 CBS 整体认知综合评分[24.5(16.1)到 29.7(20.5);p=0.02]。所有 CBS 域均得到改善。

结论

干预 6 个月后,多项认知功能测量指标得到改善。我们的结果支持 OCI 的多模式个体化治疗方法的可行性和效果,值得进一步研究。

相似文献

1
Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.认知衰退人群的个性化生活方式干预中的认知改善观察。
J Alzheimers Dis. 2023;94(3):993-1004. doi: 10.3233/JAD-230004.
2
Vitamin E for Alzheimer's dementia and mild cognitive impairment.维生素E用于治疗阿尔茨海默病性痴呆和轻度认知障碍。
Cochrane Database Syst Rev. 2017 Apr 18;4(4):CD002854. doi: 10.1002/14651858.CD002854.pub5.
3
Vitamin E for Alzheimer's dementia and mild cognitive impairment.维生素E用于治疗阿尔茨海默病性痴呆和轻度认知障碍。
Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD002854. doi: 10.1002/14651858.CD002854.pub4.
4
Folic acid with or without vitamin B12 for cognition and dementia.叶酸联合或不联合维生素B12对认知及痴呆的影响
Cochrane Database Syst Rev. 2003(4):CD004514. doi: 10.1002/14651858.CD004514.
5
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.加兰他敏治疗阿尔茨海默病所致痴呆和轻度认知障碍。
Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4.
6
Occupational therapy for cognitive impairment in stroke patients.脑卒中患者认知障碍的作业治疗。
Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.
7
Multi-domain interventions for the prevention of dementia and cognitive decline.多领域干预措施预防痴呆和认知能力下降。
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013572. doi: 10.1002/14651858.CD013572.pub2.
8
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.抗血栓治疗预防神经影像学检查发现的小血管疾病但无痴呆的患者认知能力下降。
Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2.
9
Dance movement therapy for dementia.舞蹈运动疗法治疗痴呆症。
Cochrane Database Syst Rev. 2023 Aug 7;8(8):CD011022. doi: 10.1002/14651858.CD011022.pub3.
10
Selegiline for Alzheimer's disease.司来吉兰用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2003(1):CD000442. doi: 10.1002/14651858.CD000442.

引用本文的文献

1
Cognitive Stimulation and Its Effects on Well-Being, Executive Functions, and Brain-Derived Neurotrophic Factor in Older Adults from a Mexican Geriatric Center: A Quasi-Experimental Study.来自墨西哥一家老年医学中心的老年人认知刺激及其对幸福感、执行功能和脑源性神经营养因子的影响:一项准实验研究
Nurs Rep. 2025 Apr 30;15(5):151. doi: 10.3390/nursrep15050151.
2
Case Report: Neuropsychological Profile of a Patient With Intravascular Large B-Cell Lymphoma Following Infection and Vaccination.病例报告:感染和接种疫苗后血管内大B细胞淋巴瘤患者的神经心理学概况。
Arch Clin Neuropsychol. 2025 Aug 25;40(6):1253-1265. doi: 10.1093/arclin/acaf027.
3

本文引用的文献

1
Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer's Disease and MCI: A Review.多因素方法逆转阿尔茨海默病和 MCI 认知衰退的理由:综述。
Int J Mol Sci. 2023 Jan 14;24(2):1659. doi: 10.3390/ijms24021659.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Complementary and Integrative Medicine for Neurocognitive Disorders and Caregiver Health.补充和整合医学对神经认知障碍和照顾者健康的作用
Continuous Glucose Monitoring in Comorbid Dementia and Diabetes: The Evidence So Far.
共病性痴呆与糖尿病患者的连续血糖监测:目前的证据
J Diabetes Sci Technol. 2024 Dec 18:19322968241301058. doi: 10.1177/19322968241301058.
4
Dementia and Cognitive Decline: A HEALM Approach.痴呆与认知衰退:一种整体健康方法。
Am J Lifestyle Med. 2024 Oct 9:15598276241291508. doi: 10.1177/15598276241291508.
5
Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?肠道微生物群代谢产物:阿尔茨海默病的潜在治疗靶点?
Front Pharmacol. 2024 Sep 17;15:1459655. doi: 10.3389/fphar.2024.1459655. eCollection 2024.
6
Sustained Cognitive Improvement in Alzheimer's Disease Patients Following a Precision Medicine Protocol: Case Series.遵循精准医疗方案的阿尔茨海默病患者认知功能持续改善:病例系列
Biomedicines. 2024 Aug 6;12(8):1776. doi: 10.3390/biomedicines12081776.
7
The impact of modifiable health metrics on mortality for older adults with low cognitive function.可改变的健康指标对认知功能低下的老年人死亡率的影响。
Front Public Health. 2024 Jan 25;12:1304876. doi: 10.3389/fpubh.2024.1304876. eCollection 2024.
8
Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.精准医学方法治疗阿尔茨海默病:原理与意义。
J Alzheimers Dis. 2023;96(2):429-437. doi: 10.3233/JAD-230467.
Curr Psychiatry Rep. 2022 Sep;24(9):469-480. doi: 10.1007/s11920-022-01355-y. Epub 2022 Aug 13.
4
Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project.精准医学方法治疗阿尔茨海默病:一项成功的试点项目。
J Alzheimers Dis. 2022;88(4):1411-1421. doi: 10.3233/JAD-215707.
5
Rates of Cognitive Decline in 100 Patients With Alzheimer Disease.100例阿尔茨海默病患者的认知衰退率
Ochsner J. 2022 Summer;22(2):129-133. doi: 10.31486/toj.21.0084.
6
Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.轻度认知障碍中迟发性神经精神症状与向痴呆进展或认知恢复正常的关系。
Neurology. 2022 May 24;98(21):e2132-e2139. doi: 10.1212/WNL.0000000000200256. Epub 2022 Mar 29.
7
2022 Alzheimer's disease facts and figures.2022 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14.
8
Case Study: A Precision Medicine Approach to Multifactorial Dementia and Alzheimer's Disease.案例研究:多因素痴呆和阿尔茨海默病的精准医学方法
J Alzheimers Dis Parkinsonism. 2021;11(Suppl 5). Epub 2021 Aug 25.
9
ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline.ReCODE:一种用于逆转认知衰退的个性化、靶向性、多因素治疗方案。
Biomedicines. 2021 Sep 29;9(10):1348. doi: 10.3390/biomedicines9101348.
10
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.早期阿尔茨海默病患者使用阿杜卡努单抗的预测终生健康结局
Neurol Ther. 2021 Dec;10(2):919-940. doi: 10.1007/s40120-021-00273-0. Epub 2021 Aug 23.